Description
Tofacitinib is an inhibitor of JAK1/2/3 that is clinically used to treat myelofibrosis and rheumatoid arthritis. Tofacitinib exhibits immunosuppressive, anti-inflammatory, and antiviral activities. In vitro, tofacitinib inhibits production of inflammatory cytokines, Th4 cell differentiation, Th17 cell differentiation, and activation of STAT1, which in turn prevents induction of T-bet and generation of Th1 cells. In other cellular models, tofacitinib inhibits HIV replication and reactivation of latent HIV-1.
References
Gavegnano C, Detorio M, Montero C, et al. Ruxolitinib and Tofacitinib are Potent and Selective Inhibitors of HIV-1 Replication and Virus Reactivation in Vitro. Antimicrob Agents Chemother. 2014 Jan 13. [Epub ahead of print]. PMID: 24419350.
Yamaoka K, Tanaka Y. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib. Expert Opin Pharmacother. 2014 Jan;15(1):103-13. PMID: 4188100.
Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011 May 25;13 Suppl 1:S5. PMID: 21624184.
Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43. PMID: 21383241.
